Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA versus susceptibility-guided third-line Helicobacter pylori eradication trial
jRCT1031260299Recruiting
- Sponsor
- Hideki Mori
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vonoprazan, amoxicillin, sitafloxacin and rifabutin in Helicobacter pylori infection (2 arms), sponsored by Hideki Mori. Primary endpoint: Successful Helicobacter pylori eradication at 12 weeks after treatment completion. Started Sep 2026; status: recruiting.
02
Drugs
vonoprazanamoxicillinsitafloxacinrifabutin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCT1031260299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260299.